跳至主要内容

Medicilon assists Carephar first potassium-ion-competitive acid blocker "Carenoprazan Tablets" approved for sales in China

 On February 15, the Class 1 new drug Carenoprazan Hydrochloride Tablets, for the treatment of duodenal ulcer and reflux esophagitis, independently developed by Jiangsu Carephar Pharmaceutical (Carephar) was officially approved for sales in market.



Shanghai Medicilon Inc. (Medicilon), as a partner of Carephar, with its solid research and development capabilities, has provided Carenoprazan’s research and development from compound design to preclinical candidate compounds, as well as most of the in vitro H+K+-ATPase testing and other services and the Carenoprazan has been successfully approved.

Medicilon Drug Discovery Services
Open the door to innovative medicine with science and expertise

Drug discovery is the first stage of drug development and a key element that directly affects the success of new drug development.  As a one-stop biopharmaceutical preclinical R&D service platform, Medicilon can provide one-stop service for drug discovery after 19 years of intensive innovation.

Medicilon can undertake different kind of chemistry services such as custom synthesis, compound library construction, SAR compound synthesis and screening, and compound structure and biological activity optimization.  In terms of biology services, Medicilon could provide reparation of hybridoma antibody/genetic engineering antibody, protein expression and purification, X-ray crystal structure analysis/cryo-electron microscopy protein structure analysis, small molecule/antibody drug conjugate/antibody-dependent cell-mediated cytotoxicity detection, organoid drug screening, screening of small molecule inhibitors/agonists targeting enzymes/receptors, protein-protein/protein-small molecule affinity determination, virtual screening and computer simulation-assisted drug design, gene editing and stable cell line construction, CAR-T/CAR-NK construction and target cell killing experiments, M9 selenium medium preparation, as well as research services on the molecular mechanism of drugs.

标签：

评论

发表评论

此博客中的热门博文

Custom Synthesis

Medicilon has synthesized over 10,000 individual compounds from gram to kilogram quantities, and many compounds are synthesized with more than ten synthetic steps. The overall synthesis success rate is over 95%. High quality products from mg to kg scale Reagents, intermediates, building blocks, and scaffolds Preparation of API or reference standards Development of synthetic routes for impurities and metabolites   On-site analytical support Product delivered with COA Medicilon offers integrated drug discovery services -- Chemistry, Biology & Preclinical Services
发表评论
阅读全文

In Vitro Enzyme Activity Assay

  Kinases play extensive and important roles in signal transduction and co-ordination of complex functions. Currently, about 300 kinase inhibitors have been approved for marketing, among which receptor tyrosine kinase (RTK) inhibitors are the main ones. Medicilon provides high-quality kinase profile screening and has one-stop kinase research services from assay development, high-throughput screening to selectivity analysis. In addition, Medicilon provides many other enzyme activity screens. Wide Variety Provides 200+  in vitro  enzymatic detection methods; 100+ kinases, including CTK, RTK, AGC, CMGC and other kinase families as well as important common mutations Project Flexibility Various types of plates for screening, such as 96 and 384; Multiple flexible kinase profiles, including TK kinase family, CDK kinase family, etc., to meet different customer customization needs. Various Methods Fluorescence detection; Chemiluminescence detection; Absorbance detection LanthaScr...
发表评论
阅读全文

Pharmacokinetics Services

Pharmacokinetics Services Our pharmacokinetics department offers the clients a broad spectrum of high quality of services in the areas of in vitro ADME, in vivo pharmacokinetics and bioanalysis services, ranging from small molecules to large molecules, such as protein and antibody. The animal species involved in our services are non-human primate, canine, mice, rat, rabbit and hamster. Meanwhile, non-human primate experimental platform and isotope platform for protein/antibody are certified by the Shanghai government. Preclinical Pharmacokinetics Method development and validation (GLP,Non-GLP) Bioanalysis Pharmacokinetics (Tumor bearing rodents, Bioavailability, Crossover studies, Cassette (N in 1) dosing and analysis, effects of gender on pharmacokinetics, BBB penetration ) Stability in vehicles and plasma Drug interaction studies In vitro metabolic stability CYP 450 inhibition Plasma protein binding studies Distribution studies Excretion studies Prediction an...
发表评论
阅读全文